News
Important Only
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210
June 2 (Reuters) - Lyra Therapeutics Inc LYRA.O:LYRA THERAPEUTICS REPORTS POSITIVE RESULTS FROM THE ENLIGHTEN 2 PHASE 3 TRIAL OF LYR-210 ACHIEVING STATISTICALLY SIGNIFICANT RESULTS FOR PRIMARY AND KEY SECONDARY ENDPOINTS IN THE TREATMENT OF CHRONIC RHINOSINUSITIS (CRS)LYRA THERAPEUTICS INC - LYR-210...Reuters
Mon, Jun 2
Zai Lab Presents Positive Phase 1 Data For Zl-1310, A Dll3-Targeted Adc
June 2 (Reuters) - Zai Lab Ltd 9688.HK:ZAI LAB PRESENTS POSITIVE PHASE 1 DATA FOR ZL-1310, A DLL3-TARGETED ADC, DEMONSTRATING ROBUST ANTI-TUMOR ACTIVITY AND SAFETY IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER AT 2025 ASCO ANNUAL MEETINGReuters
Mon, Jun 2
Orion Energy Systems Inc expected to post a loss of 5 cents a share - Earnings Preview
Orion Energy Systems Inc OESX.OQ OESX.O is expected to show a fall in quarterly revenue when it reports results on June 4 (estimated) for the period ending March 31 2025The Manitowoc Wisconsin-based company is expected to report a 19.8% decrease in revenue to $21.181 million from $26.41 million a ...Reuters
Mon, Jun 2
Kymera Therapeutics Announces Positive First-In-Human Results From Phase 1 Healthy Volunteer Clinical Trial Of KT-621
June 2 (Reuters) - Kymera Therapeutics Inc KYMR.O:KYMERA THERAPEUTICS ANNOUNCES POSITIVE FIRST-IN-HUMAN RESULTS FROM PHASE 1 HEALTHY VOLUNTEER CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADERKYMERA THERAPEUTICS INC - KT-621 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTSKYMERA THERAPEUT...Reuters
Mon, Jun 2
Nervgen Pharma Reports Positive Topline Data From The Chronic Cohort Of Its Phase 1B/2A Clinical Trial Evaluating Nvg-291 In Spinal Cord Injury
June 2 (Reuters) - NervGen Pharma Corp NGEN.V:NERVGEN PHARMA REPORTS POSITIVE TOPLINE DATA FROM THE CHRONIC COHORT OF ITS PHASE 1B/2A CLINICAL TRIAL EVALUATING NVG-291 IN SPINAL CORD INJURYNERVGEN PHARMA CORP: STUDY MET ITS PRIMARY ENDPOINT BY ACHIEVING STATISTICAL SIGNIFICANCE ON ONE OF ITS TWO PRE...Reuters
Mon, Jun 2
Markel completes acquisition of marine specialist Meco
June 2 - (The Insurer) - Markel Insurance has completed its acquisition of marine-focused managing general agent Meco Group, the company said on Monday.Trading as Meco Specialty, the acquired business will sit within the specialty division of Markel International’s wholesale operation, led by Tom Hi...Reuters
Mon, Jun 2
Regeneron Pharmaceuticals - Interim Results From Ongoing Phase 2 Courage Trial
June 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:INTERIM RESULTS FROM ONGOING PHASE 2 COURAGE TRIAL CONFIRM POTENTIAL TO IMPROVE THE QUALITY OF SEMAGLUTIDE (GLP-1 RECEPTOR AGONIST)-INDUCED WEIGHT LOSS BY PRESERVING LEAN MASSREGENERON PHARMACEUTICALS INC - 35% OF SEMAGLUTIDE-INDUCED WEIGHT LOS...Reuters
Mon, Jun 2
ADVISORY-Alert incorrectly tagged to Ford withdrawn
An alert on Venu Holding's VENU.A founder being featured in a magazine profile was inadvertently tagged to automaker Ford F.N, an unrelated company, and has been withdrawn.There will be no substitute.STORY_NUMBER:nTUABF6VVCSTORY_DATE:02/06/2025STORY_TIME:12:15:03 GMTReuters
Mon, Jun 2
Reviva Announces Positive Full Dataset For 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine In Schizophrenia
June 2 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O:REVIVA ANNOUNCES POSITIVE FULL DATASET FOR 1-YEAR PHASE 3 RECOVER OPEN LABEL EXTENSION STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIAReuters
Mon, Jun 2
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy
June 2 (Reuters) - Vera Therapeutics Inc VERA.O:VERA THERAPEUTICS ANNOUNCES ATACICEPT ACHIEVED 46% PROTEINURIA REDUCTION IN ORIGIN PHASE 3 TRIAL IN ADULTS WITH IGA NEPHROPATHYVERA THERAPEUTICS INC - TO SUBMIT BLA FOR ATACICEPT TO FDA IN 4Q 2025VERA THERAPEUTICS INC - ATACICEPT SAFETY PROFILE FAVORAB...Reuters
Mon, Jun 2
Richards Packaging Income Fund Announces Acquisition Of DermapenWorld
June 2 (Reuters) - Richards Packaging Income Fund RPI_u.TO:RICHARDS PACKAGING INCOME FUND ANNOUNCES ACQUISITION OF DERMAPENWORLD®RICHARDS PACKAGING INCOME FUND - PURCHASE PRICE OF $40 MILLION FINANCED BY NEW TERM CREDIT FACILITYFurther company coverage: [RPI_u.TO]Reuters
Mon, Jun 2
